Grade 3 and above opportunistic pneumonia or drug-induced interstitial lung disease during tyrosine-kinase inhibitor treatment for advanced non-small-cell lung cancer with RET fusion mutations: coexistence of risks and opportunities
These findings provide new insights into the individualized treatment of RET + NSCLC patients and emphasize the importance of considering the overall health status of patients in treatment decisions.
Authors
- Changli Liu (ORCID: https://orcid.org/0000-0002-4531-5749)
- X. Q. Li
- Xiaotong Zhang (ORCID: https://orcid.org/0000-0002-9197-1421)
- Yunye Mao (ORCID: https://orcid.org/0009-0004-9457-6664)
- Lu Yu
- T J Li
- Xiaoran Cui
- Tong Zhang
- Fan Yang
- Yi Dong
- Min Liu
- An Wang
- Yi Hu
Institutions
- Xinjiang Medical University (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
- Chinese PLA General Hospital (CN)
- Jilin Academy of Agricultural Sciences (CN)
- PLA Academy of Military Science (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1186/s40001-025-03792-w
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00